Markus Lucerna
About
Markus Lucerna is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Cancer Research.
According to data from OpenAlex, Markus Lucerna has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 7 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Markus Lucerna's work include Atrial Fibrillation Management and Outcomes (10 papers), Angiogenesis and VEGF in Cancer (6 papers) and Cardiac Arrhythmias and Treatments (5 papers). Markus Lucerna is often cited by papers focused on Atrial Fibrillation Management and Outcomes (10 papers), Angiogenesis and VEGF in Cancer (6 papers) and Cardiac Arrhythmias and Treatments (5 papers). Markus Lucerna collaborates with scholars based in Germany, Italy and Austria. Markus Lucerna's co-authors include Raffaele De Caterina, Ladislav Pecen, Paulus Kirchhof, Diana Mechtcheriakova, Erhard Hofer, Bernd R. Binder, Matthias Clauss, Gernot Schabbauer, Giuseppe Patti and Rainer de Martin and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Journal of the American College of Cardiology.
In The Last Decade
Markus Lucerna
21 papers receiving 1.1k citations
Peers
Markus Lucerna
Kazuma Iekushi Japan
Frédérique Dol France
Andrei Seferian France
Seitaro Omoto Japan
Yvonne H. Datta United States
Constance C. F. M. J. Baaten Netherlands
F. Belgore United Kingdom
Kevin Croce United States
Randolph Hutter United States
Rosa Suades Spain
Citations per year, relative to Markus Lucerna Markus Lucerna (= 1×)
peers
Kazuma Iekushi
Countries citing papers authored by Markus Lucerna
Since
Specialization
Citations
This map shows the geographic impact of Markus Lucerna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Lucerna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Lucerna more than expected).
Fields of papers citing papers by Markus Lucerna
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Markus Lucerna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Lucerna. The network helps show where Markus Lucerna may publish in the future.
Co-authorship network of co-authors of Markus Lucerna
This figure shows the co-authorship network connecting the top 25 collaborators of Markus Lucerna. A scholar is included among the top collaborators of Markus Lucerna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Lucerna. Markus Lucerna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Saura, Cristina, Hans Wildiers, Giampaolo Bianchini, et al.. (2025). European experience of patients with HER2-positive advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: the EUROPA T-DXd study. Frontiers in Oncology. 15. 1650981–1650981.
2.
Laurentiis, Michelino De, José Á. García-Sáenz, Giampaolo Bianchini, et al.. (2024). Abstract PO3-16-12: European real-world experience of patients with HER2+ advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: first interim analysis of EUROPA T-DXd. Cancer Research. 84(9_Supplement). PO3–16.
3.
Guarneri, Valentina, François P. Duhoux, Daniel Egle, et al.. (2024). Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer. Future Oncology. 20(18). 1237–1250.
4.
Cottu, Paul, Sue Cheeseman, Peter Hall, et al.. (2024). Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records. Breast Cancer Research and Treatment. 209(2). 419–430.
5.
Patti, Giuseppe, Ladislav Pecen, Markus Lucerna, et al.. (2019). Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. The American Journal of Medicine. 132(6). 749–757.e5.
6.
Rohla, Miklós, Thomas W. Weiss, Ladislav Pecen, et al.. (2019). Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open. 9(3). e022478–e022478.
7.
Patti, Giuseppe, Ladislav Pecen, Markus Lucerna, et al.. (2018). Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. International Journal of Cardiology. 270. 160–166.
8.
Siller‐Matula, Jolanta M., Ladislav Pecen, Giuseppe Patti, et al.. (2018). Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. International Journal of Cardiology. 265. 141–147.
9.
Schnabel, Renate B., Ladislav Pecen, Markus Lucerna, et al.. (2018). Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes. Heart. 104(19). 1608–1614.
10.
Schnabel, Renate B., Ladislav Pecen, Markus Lucerna, et al.. (2018). Symptom Burden of Atrial Fibrillation and Its Relation to Interventions and Outcome in Europe. Journal of the American Heart Association. 7(11).
11.
Patti, Giuseppe, Markus Lucerna, Ilaria Cavallari, et al.. (2017). Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 69(4). 409–419.
12.
Caterina, Raffaele De, Bernd Brüggenjürgen, Harald Darius, et al.. (2017). Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. Archives of cardiovascular diseases. 111(2). 74–84.
13.
Patti, Giuseppe, Markus Lucerna, Ladislav Pecen, et al.. (2017). Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub‐Analysis From the PREFER in AF ( PRE vention o F Thromboembolic Events– E uropean R egistry in A trial F ibrillation). Journal of the American Heart Association. 6(7).
14.
Schabbauer, Gernot, Bernhard Schweighofer, Diana Mechtcheriakova, et al.. (2007). Nuclear factor of activated T cells and early growth response-1 cooperate to mediate tissue factor gene induction by vascular endothelial growth factor in endothelial cells. Thrombosis and Haemostasis. 97(6). 979–987.
15.
Lucerna, Markus, Diana Mechtcheriakova, Alexandra Kadl, et al.. (2006). Sustained Expression of Early Growth Response Protein-1 Blocks Angiogenesis and Tumor Growth. Cancer Research. 66(13). 6708–6713.
16.
Lucerna, Markus, Diana Mechtcheriakova, Alexandra Kadl, et al.. (2003). NAB2, a Corepressor of EGR-1, Inhibits Vascular Endothelial Growth Factor-mediated Gene Induction and Angiogenic Responses of Endothelial Cells. Journal of Biological Chemistry. 278(13). 11433–11440.
17.
Грубер, Флориан, Peter Hufnagl, Renate Hofer-Warbinek, et al.. (2003). Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNFα-induced PAI-1 expression. Blood. 101(8). 3042–3048.
18.
Blum, Sabine, Antje Willuweit, Stephanie Hehlgans, et al.. (2001). An Inhibitory Role of the Phosphatidylinositol 3-Kinase-signaling Pathway in Vascular Endothelial Growth Factor-induced Tissue Factor Expression. Journal of Biological Chemistry. 276(36). 33428–33434.
19.
Blum, Sabine, Katja Issbrücker, Antje Willuweit, et al.. (2001). An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression.. Journal of Biological Chemistry. 276(45). 42618–42618.
20.
Mechtcheriakova, Diana, Gernot Schabbauer, Markus Lucerna, et al.. (2001). Specificity, diversity, and convergence in VEGF and TNF‐α signaling events leading to tissue factor up regulation via EGR‐1 in endothelial cells. The FASEB Journal. 15(1). 230–242.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kazuma Iekushi Breakdown of academic impact, for papers by Frédérique Dol Breakdown of academic impact, for papers by Andrei Seferian Breakdown of academic impact, for papers by Seitaro Omoto Breakdown of academic impact, for papers by Yvonne H. Datta Breakdown of academic impact, for papers by Constance C. F. M. J. Baaten Breakdown of academic impact, for papers by F. Belgore Breakdown of academic impact, for papers by Kevin Croce Breakdown of academic impact, for papers by Randolph Hutter Breakdown of academic impact, for papers by Rosa Suades